Addition of liraglutide to insulin in patients with type 1 diabetes: A randomized placebo-controlled clinical trial of 12 weeks

Diabetes Care

Volumn 39, Issue 6, 2016, Pages 1027-1035

  Kuhadiya, Nitesh D ^a   Dhindsa, Sandeep ^a,b   Ghanim, Husam ^a   Mehta, Aditya ^a   Makdissi, Antoine ^a   Batra, Manav ^a   Sandhu, Sartaj ^a   Hejna, Jeanne ^a   Green, Kelly ^a   Bellini, Natalie ^a   Yang, Min ^c   Chaudhuri, Ajay ^a   Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CARBOHYDRATE INTAKE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; OBESITY; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; POSTPRANDIAL STATE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNITED STATES; VOMITING; WEIGHT REDUCTION; BODY WEIGHT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 1; HYPOGLYCEMIA; METABOLISM; TIME FACTOR; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIRAGLUTIDE; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; POSTPRANDIAL PERIOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 84971249932     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1136     Document Type: Article

References (16)

1. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014;371:1972-1982
2. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011;165:77-84
3. Kuhadiya ND, Malik R, Bellini NJ, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract 2013;19:963-967
4. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011; 34:1463-1468
5. Harrison LB, Mora PF, Clark GO, Lingvay I. Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Investig Med 2013;61: 40-44
6. Traina AN, Lull ME, Hui AC, Zahorian TM, Lyons-Patterson J. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes 2014; 38:269-272
7. Sarkar G, Alattar M, Brown RJ, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care 2014;37: 666-670
8. Bode B, Beck RW, Xing D, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care 2009;32: 2047-2049
9. Aljada A, Mohanty P, Ghanim H, et al. Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. Am J Clin Nutr 2004;79:682-690
10. Ghanim H, Abuaysheh S, Sia CL, et al. Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009;32:2281-2287
11. Ghanim H, Sia CL, Upadhyay M, et al. Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. Am J Clin Nutr 2010;91: 940-949
12. Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 2012;97:258-266
13. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007; 13:444-450
14. Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study. Diabetes Care 2015;38:2250-2257
15. Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2016;4:221-232
16. Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes (NN9211) [Internet], 2015. Available from http://globenewswire.com/news-release/2015/ 08/24/762981/0/en/Novo-Nordisk-completessecond-and-final-phase-3a-trial-with-liraglutideas-adjunct-therapy-to-insulin-for-people-withtype-1-diabetes-NN9211.html. Accessed 26 March 2016